-A new approach to beating herpes by inducing antibodies that mediate the killing of infected cells
-Participants include Johnson & Johnson Innovation - JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; Founders Fund.
The second annual Einstein-Montefiore Presidential Lecture featured lectures by Betsy C. Herold, M.D., and William R. Jacobs, Jr., Ph.D. on their collaborative efforts to develop a vaccine for herpes viruses HSV-1 and HSV-2. The novel vaccine they've engineered has shown remarkable results in early testing and plans are now under way to assess the vaccine in Phase 1 clinical trials.
On Tuesday, May 1, 2018, Drs. William Jacobs, Jr., and Betsy Herold presented on their collaborative research leading to development of a promising herpes vaccine.
American Society for Microbiology published Dr. Jacobs interview "Tuberculosis Treatment and Mycobacterial Genetics" on the March 15th episode of Meet the Microbiologist, hosted by Julie Wolf.
You can listen to the podcast here, or on your mobile device with the ASM Podcast app.
Subscribe to Meet the Microbiologist on on iPhone, Android, RSS, or by email.
In February the Proceedings of the National Academy of Sciences published a contribution article from the Jacobs lab describing two deletions encoding an enzyme of the respiratory chains in Mycobacterium tuberculosis profoundly effect the viability and virulence of the mycobacterium. Screening compound libraries against both genes will lead to promising drug candidates to fight tuberculosis.
Read the article here.
In a paper recently published in Antimicrobial Agents and Chemotherapy, Dr. Catherine Vilcheze discusses her experiments that demonstrate Vitamin C in combination with first-line TB drugs (isoniazid and rifampicin) will kill an M. tuberculosis infection in mice.
Read the paper here
On January 4th Steve Baragona from Voice of America interviewed Dr. Jacobs about these findings in an article you can read here.
The latest paper from the Jacobs Lab published in PNAS on April 10 describes how the human approved drug N-acetylcysteine (NAC) in addition to TB drugs could help significantly shorten chemotherapy time for tuberculosis patients.
Read the paper here!
Read Christopher A. Kerantzas' thesis paper published in mBio on March 14!
Earlier this year Dr. Michael Berney, formally of the Jacobs Group, was appointed an Assistant Professor in the Microbiology and Immunology Department at the Albert Einstein College of Medicine. Congratulations!
Describes the ESX-3 type VII secretion system's role in iron acquisition in M. tuberculosis
Describes the how vaccine vector HSV ΔgD completely protects against highly virulent clinical isolates of HSV-1 and HSV-2
Describes the DS6A reporter phage that uniquely plaques to M. tuberculosis. This is the PhD Thesis paper for Dr. Oren Meyer!
Describes the development of dual-reporter mycobacteriophages that cause a culture of M. tuberculosis to glow green inititally and glow red when entering a persister state.
JoAnn Tufariello wrote a paper for mBio describing the complete genome for the emerging pathogen Mycobacterium haemophilum, it's need for iron to grow in vivo, and it's close relationship to the causative agent of leprosy, M. leprae.
Read the paper a mBio
A Spotlight Article about the latest PNAS paper from Drs Michael Berney and Linda Berney-Meyer on “Methionine-less death in M. tuberculosis” has just been published in Trends of Microbiology (CellPress).
